Abstract:Our previous study has found this new BT technique could not only improve the target dose coverage, but also maintain the organ at risk (OARs) to a reasonable lower dose for advanced cervical cancer patients. The aim of this study is to explore potentially prognostic factors for survival and toxicity for the first time in the world. Sixty-three cervical cancer patients (FIGO stage IIB-IVA) who received ICBT+IMRT were retrospectively analyzed. They all received concomitent chemoradiotherapy. External body radiotherapy was performed with IMRT. A total dose of 45-50Gy was applied in 25 fractions for 5 weeks. The patients underwent 4 fractions BT at 6-6.5Gy/fraction twice a week. The targets and OARs were contoured by the professional physicians according to the GEC ESTRO recommendations. The complementary IMRT plan was delivered immediately after HDR-ICBT, with the applicator in position. D90, D100, V100, Vpd, V2xpd, volumes of target and D0.1cc, D1cc, D2cc, DICRU of OARs were recorded. CTCAE was used to evaluate the acute and late toxicities. The log-rank test and Cox regression mode were used for univariate and multivariate survival prognostic analyses. Logistic regression analysis was used for the toxic prognostic analyses. The 2-year local control rate (LC), distant metastasis free rate and overall survival rate were 94.8%, 84.9% and 91.6%. Both acute and late incidence of proctitis, rectal hemorrhage, small intestine obstruction and cystitis were low, the grade was not exceed G4 (Table 1.). None rectum and bladder perforation has occurred. The mean D90 of GTV, HR-CTV and IR-CTV were 93.3±4.3Gy, 81.8±2.5Gy, and 72.8±1.1Gy, and the mean D2cc of bladder, rectum, sigmoid and small intestine were lower than 75Gy. For BT dose, the mean D100 of GTV, HR-CTV and IR-CTV were 32.1±2.6, 23.2±2.2 and 14.7±1.3Gy, the mean V100 of HR-CTV and IR-CTV were 92.9%±1.2%, 92.7%±1.3%, and the mean DICRU of rectum and bladder were 22.3±4.6Gy and 18.3±3.3Gy. The D100 of IR-CTV was a prognostic factor for LC in univariate analyses among these factors (p = 0.041), but it had no statistical significance in multivariate analysis. The DICRU of bladder was a prognostic factor for the late cystitis (p = 0.045). This promising new technique could achieve the relatively higher local control rate and lower acute and late toxicity incidence. D100 of IR-CTV might be considered as a new potentially prognostic indicator for LC. DICRU of bladder still remained a prognostic factor for late cystitis, and it might have a more important role than D2cc.Scientific Abstract 2697; TableIncidence and grade of acute and late toxicityToxicityG1-2(%)G3(%)G4-5(%)Acute proctitis30.200Acute rectal hemorrhage1.600Acute small intestinal obstruction1.600Acute cystitis15.91.60Late proctitis3.200Late small intestinal obstruction1.61.60Late cystitis4.81.60Late rectal hemorrhage000 Open table in a new tab

The Efficacy and Late Toxicities of Computed Tomography-based Brachytherapy with Intracavitary and Interstitial Technique in Advanced Cervical Cancer.

Comparison of Computed Tomography- and Magnetic Resonance Imaging-Based Target Delineation for Cervical Cancer Brachytherapy

Comparison of Computed Tomography and Magnetic Resonance Imaging in Cervical Cancer Brachytherapy: A Systematic Review.

Dosimetry and Short Term Effect Comparison of CT-guided Interstitial Brachytherapy and Intracavitary Brachytherapy for Locally Advanced Cervical Cancer

Dosimetric Study of Three-Dimensional Image-Quided Brachytherapy Combined with Intracavitary/ Interstitial Brachytherapy in Locally Advanced Cervical Cancer

Clinical outcomes of conventional <scp>HDR</scp> intracavitary brachytherapy combined with complementary applicator‐guided intensity modulated radiotherapy boost in patients with bulky cervical tumor

The Correlation Between DVH at CT-image Based 192ir Intracavitary Brachytherapy and Effects or Complications for Patients with Locally Advanced Cervical Cancer

Late Rectal Toxicity Determined by Dose–volume Parameters in Computed Tomography‐based Brachytherapy for Locally Advanced Cervical Cancer

Preliminary Clinical Outcomes and Dosimetry Study on Adaptive Imrt Integrated Hdr Brachytherapy in Local Advanced Uterine Cervical Cancer.

Dosimetric Analysis of CT-guided Salvage Interstitial Brachytherapy for Recurrent Cervical Cancer

Prognostic Factors For Toxicity And Survival In Advanced Cervical Cancer Patients Treated With High-Dose-Rate (Hdr)-Intracavitary Brachytherapy (Icbt) Combined With Complementary Intensity Modulated Radiation Therapy (Imrt)

Technique Introduction of Computed Tomographyguided Interstitial Brachytherapyanda Comparison of Dosimetry with Conventional Intracavitary Brachytherapy for Locally Advanced Cervical Cancer

CT-guided Interstitial Brachytherapy for Locally Advanced Cervical Cancer:Introduction of the Technique and Report of Dosimetry

Clinical Outcomes of MRI-Guided Adaptive Brachytherapy for Each Fraction in Locally Advanced Cervical Cancer: A Single Institution Experience.

Efficacy and safety of the CT-guided three-dimensional brachytherapy combined with three-dimensional conformal radiotherapy in patients with locally middle-and late-stage cervical cancer

Clinical efficacy of MRI image-based three-dimensional brachytherapy in locally advanced cervical cancer

Clinical Preliminary Observation on Image-Guided Brachytherapy for Cervical Cancer

Results of Definitive (Chemo)radiotherapy Using Computed Tomography-based Brachytherapy for Cervical Cancer

Image-guided interstitial brachytherapy for recurrent cervical cancer after radiotherapy: A single institution experience

Clinical efficacy of HDR brachytherapy with concomitant complementary IMRT boost for bulky uterine cervical cancer

Factors affecting D90 High-risk Clinical Target Volumes (HR-CTV dose) of intracavitary and interstitial brachytherapy in locally advanced cervical cancer